A 49-year-old woman was diagnosed with an ER+, PR-, HER2+, BRCA- De Novo metastatic breast cancer including bone, liver, and lymph node involvement. Standardized care included a five-month treatment period with targeted chemotherapy and radiotherapy, and a ketogenic diet. The patient also began a course of whole plant cannabinoid-based therapy and psilocybin-assisted psychotherapy at macro and intermittent micro-doses. Whole plant cannabis medicines require many stages and quality controls to ensure consistent phytocannabinoid content across batches.1 To consistently reproduce these formulations, specialized cannabis genetic selection, cultivation, and extraction techniques were required as well as chromatography analysis across each batch. The whole-plant cannabis formulations administered to this patient contain the major cannabinoids THC and CBD as well as a mixture of over 140+ other minor cannabinoids, terpenes, and flavonoids.